What does the Chinese military want with your unborn baby’s genetic data?
By Arwa Mahdawi,
The Guardian
| 07. 10. 2021
The BGI group has used data from its popular prenatal test to help the People’s Liberation Army improve ‘population quality’ but they are far from the only ones normalizing eugenics
Your unborn baby is already being monetized
Could data harvested from millions of pregnant women pave the way for genetically enhanced super-soldiers? According to a recent Reuters investigation, BGI Group, the manufacturers of a popular prenatal test, is working with the Chinese military towards that very goal.
BGI group offers a test called Nifty (“Non-Invasive Fetal TrisomY”), which is offered in more than 50 countries and is used to look for genetic abnormalities such as Down’s syndrome early on in a pregnancy. According to Reuters, more than 8 million women have taken these tests, and BGI has used the genetic data it has collected to help the Chinese military improve “population quality”. Reuters reports that US government advisers have warned that access to this massive databank could “propel China to dominate global pharmaceuticals, and also potentially lead to genetically enhanced soldiers, or engineered pathogens to target the US population or food supply”. BGI has issued a statement rejecting these claims.
“China is stealing your intimate data for evil purposes” is a popular genre in western journalism – see, for...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...